Clinical Trial Update: A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

This document notes a Phase 2 trial of PF-04856884 in recurrent glioblastoma that has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• PF-04856884

Snippet

Sponsor: Pfizer | Conditions: Glioblastoma | Phase 2 | Status: WITHDRAWN